[{"id":"09a2d6c3-0189-486e-8048-e063641e4790","acronym":"","url":"https://clinicaltrials.gov/study/NCT07480694","created_at":"2026-03-28T01:39:28.152Z","updated_at":"2026-03-28T01:39:28.152Z","phase":"","brief_title":"Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC","source_id_and_acronym":"NCT07480694","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 03/01/2026","start_date":" 03/01/2026","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2026-03-18"},{"id":"f5ce8c06-3250-40ff-b25a-dd3430d92b46","acronym":"","url":"https://clinicaltrials.gov/study/NCT07078604","created_at":"2025-07-26T13:31:46.938Z","updated_at":"2025-07-26T13:31:46.938Z","phase":"Phase 2","brief_title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT07078604","lead_sponsor":"University of Washington","biomarkers":" ENG","pipe":"","alterations":" ","tags":["ENG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • daunorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • EP-101 STEMVAC • Leukine (sargramostim)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-07-22"},{"id":"74157a34-d6de-4ba9-9962-025f2effcf7f","acronym":"ALPHABET","url":"https://clinicaltrials.gov/study/NCT05063786","created_at":"2021-10-01T11:54:26.039Z","updated_at":"2025-02-25T12:37:59.796Z","phase":"Phase 3","brief_title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","source_id_and_acronym":"NCT05063786 - ALPHABET","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" ER positive • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Piqray (alpelisib) • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-24"},{"id":"9563a22f-1431-499b-ba51-cc38d3b74ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04345913","created_at":"2021-01-18T21:01:42.609Z","updated_at":"2025-02-25T13:40:07.851Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT04345913","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PIK3CA • PGR • PTEN","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PIK3CA mutation","tags":["ER • PIK3CA • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-21"},{"id":"e34a5a55-d8a1-4469-8532-07c6096c4f21","acronym":"KELLY","url":"https://clinicaltrials.gov/study/NCT03222856","created_at":"2021-01-18T15:54:23.632Z","updated_at":"2025-02-25T14:01:19.405Z","phase":"Phase 2","brief_title":"Ph II Study of Pembrolizumab \u0026 Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines \u0026 Taxanes","source_id_and_acronym":"NCT03222856 - KELLY","lead_sponsor":"MedSIR","biomarkers":" HER-2 • PD-L1 • ER • PGR • TMB","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Halaven (eribulin mesylate)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 12/14/2017","start_date":" 12/14/2017","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 12/23/2020","study_completion_date":" 12/23/2020","last_update_posted":"2025-02-19"},{"id":"f6a27acf-7978-4c4b-a907-56c547d54b2a","acronym":"Morpheus-TNBC","url":"https://clinicaltrials.gov/study/NCT03424005","created_at":"2021-01-18T16:53:25.262Z","updated_at":"2025-02-25T15:17:38.740Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT03424005 - Morpheus-TNBC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • PIK3CA","pipe":" | ","alterations":" PD-L1 expression • PIK3CA mutation","tags":["HER-2 • PD-L1 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)"],"overall_status":"Recruiting","enrollment":" Enrollment 580","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 05/03/2028","primary_completion_date":" 05/03/2028","study_txt":" Completion: 05/03/2028","study_completion_date":" 05/03/2028","last_update_posted":"2025-02-10"},{"id":"2aaa57e7-ec75-44f1-85ec-6f02f055294b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06590558","created_at":"2025-02-25T16:41:20.201Z","updated_at":"2025-02-25T16:41:20.201Z","phase":"Phase 1","brief_title":"Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer","source_id_and_acronym":"NCT06590558","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RIPK1","pipe":"","alterations":" ","tags":["RIPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • tolinapant (ASTX660)"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 08/04/2025","start_date":" 08/04/2025","primary_txt":" Primary completion: 05/17/2027","primary_completion_date":" 05/17/2027","study_txt":" Completion: 05/17/2027","study_completion_date":" 05/17/2027","last_update_posted":"2025-02-06"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"63838d90-f82c-44d3-afff-603ca5347be5","acronym":"EPOCH","url":"https://clinicaltrials.gov/study/NCT05619913","created_at":"2023-11-28T05:15:42.216Z","updated_at":"2025-02-25T13:36:18.599Z","phase":"Phase 2","brief_title":"EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma","source_id_and_acronym":"NCT05619913 - EPOCH","lead_sponsor":"Australia New Zealand Gynaecological Oncology Group","biomarkers":" HMGA2","pipe":" | ","alterations":" HMGA2 expression","tags":["HMGA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HMGA2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Halaven (eribulin mesylate)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-04"},{"id":"bf66f941-6a2a-46d7-85ee-195ce47af690","acronym":"OlympiAD","url":"https://clinicaltrials.gov/study/NCT02000622","created_at":"2021-01-17T17:37:41.420Z","updated_at":"2025-02-25T16:13:35.803Z","phase":"Phase 3","brief_title":"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.","source_id_and_acronym":"NCT02000622 - OlympiAD","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • capecitabine • Halaven (eribulin mesylate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 302","initiation":"Initiation: 03/27/2014","start_date":" 03/27/2014","primary_txt":" Primary completion: 12/09/2016","primary_completion_date":" 12/09/2016","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-20"},{"id":"ffa36ee9-c0da-420e-bc20-b503b2b0b217","acronym":"TBCRC 058","url":"https://clinicaltrials.gov/study/NCT06099769","created_at":"2023-10-25T19:14:04.278Z","updated_at":"2025-02-25T15:36:36.074Z","phase":"Phase 2","brief_title":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","source_id_and_acronym":"NCT06099769 - TBCRC 058","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PD-L1 • AR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • AR positive","tags":["HER-2 • PD-L1 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • capecitabine • Xtandi (enzalutamide) • Halaven (eribulin mesylate) • Korlym (mifepristone) • Mifeprex (mifepristone)"],"overall_status":"Recruiting","enrollment":" Enrollment 201","initiation":"Initiation: 10/18/2023","start_date":" 10/18/2023","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-01-20"},{"id":"babb040a-8e58-46a5-a8a3-a326e81d8c49","acronym":"MORAb-202-G000-201","url":"https://clinicaltrials.gov/study/NCT04300556","created_at":"2021-01-18T20:51:39.021Z","updated_at":"2025-02-25T14:29:08.502Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","source_id_and_acronym":"NCT04300556 - MORAb-202-G000-201","lead_sponsor":"Eisai Inc.","biomarkers":" HER-2 • BRAF • ER • ALK • PGR • ROS1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • BRAF • ER • ALK • PGR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • prednisone • dexamethasone • farletuzumab ecteribulin (MORAb-202) • farletuzumab (MORAB-003) • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 142","initiation":"Initiation: 08/06/2020","start_date":" 08/06/2020","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-12-09"},{"id":"6fb8362c-e7e1-47e4-848c-a1f5eb984935","acronym":"KEYNOTE-G08","url":"https://clinicaltrials.gov/study/NCT05824975","created_at":"2024-01-29T17:20:35.977Z","updated_at":"2025-02-25T16:18:44.543Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","source_id_and_acronym":"NCT05824975 - KEYNOTE-G08","lead_sponsor":"GI Innovation, Inc.","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • doxorubicin hydrochloride • Halaven (eribulin mesylate)"],"overall_status":"Recruiting","enrollment":" Enrollment 358","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 11/12/2025","primary_completion_date":" 11/12/2025","study_txt":" Completion: 04/24/2027","study_completion_date":" 04/24/2027","last_update_posted":"2024-11-25"},{"id":"7764dbff-7eb4-429d-95dc-1ab78ecc2834","acronym":"SOLARA","url":"https://clinicaltrials.gov/study/NCT04711824","created_at":"2021-01-19T20:52:35.671Z","updated_at":"2025-02-25T14:59:38.736Z","phase":"Phase 1/2","brief_title":"Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases","source_id_and_acronym":"NCT04711824 - SOLARA","lead_sponsor":"Colette Shen","biomarkers":" HER-2 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA mutation","tags":["HER-2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/09/2022","start_date":" 03/09/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-11-22"},{"id":"1f6d130c-d54f-44a7-bb36-f1f10bd11cce","acronym":"","url":"https://clinicaltrials.gov/study/NCT02623972","created_at":"2021-01-18T12:45:04.793Z","updated_at":"2025-02-25T13:34:38.183Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer","source_id_and_acronym":"NCT02623972","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Halaven (eribulin mesylate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/26/2016","start_date":" 02/26/2016","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-09-19"},{"id":"1c9daf03-acbe-412b-99d6-f63aac6d1d20","acronym":"EVER-132-002","url":"https://clinicaltrials.gov/study/NCT04639986","created_at":"2021-01-19T20:38:27.058Z","updated_at":"2024-07-02T16:34:26.121Z","phase":"Phase 3","brief_title":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","source_id_and_acronym":"NCT04639986 - EVER-132-002","lead_sponsor":"Gilead Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 331","initiation":"Initiation: 11/23/2020","start_date":" 11/23/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-14"},{"id":"bd75f6cb-9c61-46b7-9c32-2458d8550dad","acronym":"BRIA-ABC","url":"https://clinicaltrials.gov/study/NCT06072612","created_at":"2023-10-10T15:12:12.246Z","updated_at":"2024-07-02T16:34:26.318Z","phase":"Phase 3","brief_title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","source_id_and_acronym":"NCT06072612 - BRIA-ABC","lead_sponsor":"BriaCell Therapeutics Corporation","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • capecitabine • cyclophosphamide • Halaven (eribulin mesylate) • Zynyz (retifanlimab-dlwr) • Bria-IMT (SV-BR-1-GM)"],"overall_status":"Recruiting","enrollment":" Enrollment 404","initiation":"Initiation: 12/05/2023","start_date":" 12/05/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-13"},{"id":"6230ef3b-69cf-45e4-9b66-1a66fc59f463","acronym":"","url":"https://clinicaltrials.gov/study/NCT05041101","created_at":"2021-09-10T16:57:30.103Z","updated_at":"2024-07-02T16:34:36.959Z","phase":"Phase 1/2","brief_title":"Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer","source_id_and_acronym":"NCT05041101","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • PGR • CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2 • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • grapiprant (RQ-00000007)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/04/2021","start_date":" 11/04/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-10"},{"id":"43fbfbcb-f326-4024-95a0-b6bf5afd97c2","acronym":"DETECT V","url":"https://clinicaltrials.gov/study/NCT02344472","created_at":"2021-01-18T11:08:55.334Z","updated_at":"2025-02-25T13:34:30.541Z","phase":"Phase 3","brief_title":"Detect V / CHEVENDO (Chemo vs. Endo)","source_id_and_acronym":"NCT02344472 - DETECT V","lead_sponsor":"Prof. Wolfgang Janni","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • capecitabine • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 271","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-06-04"},{"id":"46b13e59-20b7-43c0-af98-d56ecbb4b8e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03237780","created_at":"2021-01-18T15:59:59.860Z","updated_at":"2024-07-02T16:34:58.887Z","phase":"Phase 2","brief_title":"Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer","source_id_and_acronym":"NCT03237780","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • Halaven (eribulin mesylate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 07/20/2018","start_date":" 07/20/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"7804b598-a4ee-4247-b0fd-55fd2504d527","acronym":"","url":"https://clinicaltrials.gov/study/NCT02035813","created_at":"2021-01-18T09:20:22.799Z","updated_at":"2024-07-02T16:34:58.978Z","phase":"Phase 2","brief_title":"DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).","source_id_and_acronym":"NCT02035813","lead_sponsor":"Prof. Wolfgang Janni","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HR negative • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HR negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • Halaven (eribulin mesylate)"],"overall_status":"Completed","enrollment":" Enrollment 116","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 01/10/2024","primary_completion_date":" 01/10/2024","study_txt":" Completion: 01/10/2024","study_completion_date":" 01/10/2024","last_update_posted":"2024-06-04"},{"id":"b6d223e7-2b21-4043-9c4a-6bf6dab3f345","acronym":"SABINA","url":"https://clinicaltrials.gov/study/NCT05810870","created_at":"2023-04-12T14:03:37.667Z","updated_at":"2024-07-02T16:34:59.522Z","phase":"Phase 2","brief_title":"PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin","source_id_and_acronym":"NCT05810870 - SABINA","lead_sponsor":"MedSIR","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • izorlisib (MEN1611)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/24/2023","start_date":" 05/24/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-06-03"},{"id":"f89835c0-06e4-4e0a-885b-6ba816427d90","acronym":"","url":"https://clinicaltrials.gov/study/NCT03202316","created_at":"2021-01-18T15:47:27.316Z","updated_at":"2024-07-02T16:34:59.898Z","phase":"Phase 2","brief_title":"Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer","source_id_and_acronym":"NCT03202316","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib) • Halaven (eribulin mesylate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/11/2017","start_date":" 08/11/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-31"},{"id":"363c4301-48c3-4930-8568-cf045174c019","acronym":"ARETHA","url":"https://clinicaltrials.gov/study/NCT05570253","created_at":"2022-10-06T13:55:55.168Z","updated_at":"2024-07-02T16:35:00.755Z","phase":"Phase 2","brief_title":"A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer","source_id_and_acronym":"NCT05570253 - ARETHA","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • evexomostat (SDX-7320)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 10/03/2022","start_date":" 10/03/2022","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2024-05-27"}]